Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Glaxosmithkline Biologicals Sa patents


Recent patent applications related to Glaxosmithkline Biologicals Sa. Glaxosmithkline Biologicals Sa is listed as an Agent/Assignee. Note: Glaxosmithkline Biologicals Sa may have other listings under different names/spellings. We're not affiliated with Glaxosmithkline Biologicals Sa, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxosmithkline Biologicals Sa-related inventors


Immunogenic compositions

A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.... Glaxosmithkline Biologicals Sa

Oil/surfactant mixtures for self-emulsification

Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and surfactant with aqueous material. The oil/surfactant compositions can be mixed with an excess volume of aqueous material to spontaneously... Glaxosmithkline Biologicals Sa

Compositions and uses

The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.... Glaxosmithkline Biologicals Sa

Multiple variants of meningococcal protein nmb1870

Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants.... Glaxosmithkline Biologicals Sa

Adjuvant compositions comprising a non-ionic isotonicity agent

The present invention relates to an aqueous adjuvant composition comprising a TLR-4 agonist and a saponin in a liposomal formulation and a non-ionic isotonicity agent having low salt concentrations.... Glaxosmithkline Biologicals Sa

Immunogenic bacterial vesicles with outer membrane proteins

Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its... Glaxosmithkline Biologicals Sa

Compositions and methods for protein glycosylation

Described herein are oligosaccharyl transferases for use in N-glycosylating proteins of interest in vitro and in host cells. Methods for using such oligosaccharyl transferases, nucleic acids encoding such oligosaccharyl transferases, and host cells comprising such oligosaccharyl transferases are also provided herein. Glycoconjugates generated by using such oligosaccharyl transferases are also... Glaxosmithkline Biologicals Sa

A a large scale virus purification

Methods of producing and purifying viruses using density gradient ultracentrifugation. The methods are suitable for large scale production, and for viruses produced in eggs or in cell culture.... Glaxosmithkline Biologicals Sa

Cytomegalovirus antigens and uses thereof

This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.... Glaxosmithkline Biologicals Sa

Adjuvanting meningococcal factor h binding protein

Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge... Glaxosmithkline Biologicals Sa

Purification of streptococcal capsular polysaccharide

A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.... Glaxosmithkline Biologicals Sa

Staphylococcus aureus proteins and nucleic acids

The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.... Glaxosmithkline Biologicals Sa

Compositions for immunising against staphylococcus aureus

An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.... Glaxosmithkline Biologicals Sa

Recombinant self-replicating polycistronic rna molecules

This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing... Glaxosmithkline Biologicals Sa

Poxviral vaccines

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.... Glaxosmithkline Biologicals Sa

Escherichia coli vaccine combination

The invention provides an immunogenic composition comprising a combination of (i) bacterial Ig-like domain protein fragment (orf405B) having the amino acid sequence set forth in SEQ ID NO:2 or a protein having at least 80% similarity thereto, and (ii) putative Lipoprotein (orf3526) having the amino acid sequence set forth in... Glaxosmithkline Biologicals Sa

Immunogenic proteins and compositions

The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS)... Glaxosmithkline Biologicals Sa

Multiple variants of meningococcal protein nmb1870

Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants.... Glaxosmithkline Biologicals Sa

Method of treatment

The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii)... Glaxosmithkline Biologicals Sa

Conjugation of streptococcal capsular saccharides

Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive amination of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method,... Glaxosmithkline Biologicals Sa

Oil-in-water emulsion influenza vaccine

The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an... Glaxosmithkline Biologicals Sa

Oil-in-water emulsions that contain nucleic acids

This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the... Glaxosmithkline Biologicals Sa

Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 are Streptococcus agalactiae antigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising... Glaxosmithkline Biologicals Sa

Modified meningococcal fhbp polypeptides

The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.... Glaxosmithkline Biologicals Sa

Clostridium difficile immunogenic composition

Immunogenic compositions comprising isolated Clostridium difficile CDTb proteins, including modified proteins, and fusion proteins comprising a CDTa protein and a CDTb protein.... Glaxosmithkline Biologicals Sa

Cationic oil-in-water emulsions

This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged... Glaxosmithkline Biologicals Sa

Process for producing influenza vaccine

A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100™) to the resulting split virus preparation; and (iv) filtering... Glaxosmithkline Biologicals Sa

Novel preventing or treating m tuberculosis infection

The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic... Glaxosmithkline Biologicals Sa

Combination neisserial compositions

Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N. meningitidis and N. gonorrhoeae.... Glaxosmithkline Biologicals Sa

Mutant staphylococcal antigens

Mutant protein A of Staphylococcus aureus (SpA) with decreased affinity for the Fcγ portion of human IgG is provided.... Glaxosmithkline Biologicals Sa

Immunogenic combinations

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods... Glaxosmithkline Biologicals Sa

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.... Glaxosmithkline Biologicals Sa

Expression system

Compositions and methods related to periplasmic expression of a toxin including diphtheria toxin or CRM197 are provided herein.... Glaxosmithkline Biologicals Sa

Adjuvanting meningococcal factor h binding protein

Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge... Glaxosmithkline Biologicals Sa

Uses of parasite macrophage migration inhibitory factors

This invention relates to compositions (e.g. vaccine compositions) which can be used to provide a subject with protective immunity against a parasite infection. The compositions comprise: (i) an immunologically effective amount of a nucleic acid (e.g. a nucleic acid-based vaccine) comprising a sequence which encodes a parasite macrophage migration inhibitory... Glaxosmithkline Biologicals Sa

04/13/17 / #20170100472

Combination vaccines with serogroup b meningococcus and d/t/p

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080076

Heterologous expression of neisserial proteins

Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080077

Heterologous expression of neisserial proteins

Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.... Glaxosmithkline Biologicals Sa

03/23/17 / #20170080084

Oil/surfactant mixtures for self-emulsification

Oil-in-water emulsions with small droplet sizes can be formed without requiring either microfluidisation or heating to cause phase inversion, but rather by simple mixing of a pre-mixed composition of oil and a surfactant component comprising at least one surfactant component with aqueous material. The HLB value of the surfactant component... Glaxosmithkline Biologicals Sa

03/16/17 / #20170073716

Purification of secreted polysaccharides from s. agalactiae

The invention relates to bacterial mutants, particularly from Streptococcus agalactiae, that secrete capsular polysaccharide and methods of purifying the secreted bacterial capsular polysaccharides from culture medium. The extracted polysaccharides are useful for producing vaccines comprising the polysaccharides alone or conjugated to proteins.... Glaxosmithkline Biologicals Sa

03/16/17 / #20170071967

Immunogenic liposomal formulation

A liposomal composition comprising a liposome and an aminoalkansulfonic buffer is described and claimed.... Glaxosmithkline Biologicals Sa

03/16/17 / #20170072033

Liposomal compositions for mucosal delivery

A liposomal composition comprising lipids which form a liposomal lipid bilayer, with phospholipid-PEG conjugates incorporated into the liposomal lipid bi-layer, and a chitosan or chitosan derivative is described and claimed.... Glaxosmithkline Biologicals Sa

02/16/17 / #20170043004

Capsular polysaccharide solubilisation and combination vaccines

Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Glaxosmithkline Biologicals Sa

02/16/17 / #20170044571

Chimpanzee adenoviral vector-based filovirus vaccines

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).... Glaxosmithkline Biologicals Sa

02/09/17 / #20170035900

Modified host cells and uses thereof

Described herein are modified host cells useful in the production of bioconjugates that can be used to vaccinate subjects against infection with Pseudomonas. The genomes of the modified host cells described herein comprise genes that encode proteins involved in glyosylation of proteins as well as genes specific to the production... Glaxosmithkline Biologicals Sa

01/12/17 / #20170008932

Uspa2 protein constructs and uses thereof

The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising... Glaxosmithkline Biologicals Sa

01/12/17 / #20170008933

Modified meningococcal fhbp polypeptides

Modified meningococcal fHbp polypeptides with increased stability.... Glaxosmithkline Biologicals Sa








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxosmithkline Biologicals Sa in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxosmithkline Biologicals Sa with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###